Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Expression of phosphofructokinase in Neisseria meningitidis.

Baart GJ, Langenhof M, van de Waterbeemd B, Hamstra HJ, Zomer B, van der Pol LA, Beuvery EC, Tramper J, Martens DE.

Microbiology. 2010 Feb;156(Pt 2):530-42. doi: 10.1099/mic.0.031641-0. Epub 2009 Oct 1.

2.

A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process.

Streefland M, Van Herpen PF, Van de Waterbeemd B, Van der Pol LA, Beuvery EC, Tramper J, Martens DE, Toft M.

Biotechnol Bioeng. 2009 Oct 15;104(3):492-504. doi: 10.1002/bit.22425.

PMID:
19598176
3.

Modeling Neisseria meningitidis B metabolism at different specific growth rates.

Baart GJ, Willemsen M, Khatami E, de Haan A, Zomer B, Beuvery EC, Tramper J, Martens DE.

Biotechnol Bioeng. 2008 Dec 1;101(5):1022-35. doi: 10.1002/bit.22016.

PMID:
18942773
4.

Evaluation of a critical process parameter: oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis.

Streefland M, van de Waterbeemd B, Kint J, van der Pol LA, Beuvery EC, Tramper J, Martens DE.

Biotechnol Bioeng. 2009 Jan 1;102(1):161-7. doi: 10.1002/bit.22030.

PMID:
18683249
5.

Scale-up for bulk production of vaccine against meningococcal disease.

Baart GJ, de Jong G, Philippi M, van't Riet K, van der Pol LA, Beuvery EC, Tramper J, Martens DE.

Vaccine. 2007 Aug 21;25(34):6399-408. Epub 2007 Jun 26.

PMID:
17658670
6.

Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes.

Baart GJ, Zomer B, de Haan A, van der Pol LA, Beuvery EC, Tramper J, Martens DE.

Genome Biol. 2007;8(7):R136.

7.

PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease.

Streefland M, van de Waterbeemd B, Happé H, van der Pol LA, Beuvery EC, Tramper J, Martens DE.

Vaccine. 2007 Apr 20;25(16):2994-3000. Epub 2007 Jan 22.

PMID:
17313999
8.

Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus.

Piirainen L, Stenvik M, Roivainen M, Eskola J, Beuvery EC, Hovi T.

Vaccine. 1999 Mar 5;17(9-10):1084-90.

PMID:
10195618
9.

In vitro determination of antigen quality: biosensor analysis and fluorescence spectroscopy.

Kersten GF, Jiskoot W, Hazendonk T, Beuvery EC.

Dev Biol Stand. 1998;92:295-300.

PMID:
9554284
10.

Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.

Sawyer LA, Wood D, Ferguson M, Crainic R, Beuvery EC, McInnis J, Albrecht P.

Biologicals. 1997 Sep;25(3):299-306.

PMID:
9324998
11.

A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.

Wood DJ, Heath AB, Kersten GF, Hazendonk T, Lantinga M, Beuvery EC.

Biologicals. 1997 Mar;25(1):59-64.

PMID:
9167009
12.

Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.

Taffs RE, Chernokhvostova YV, Dragunsky EM, Nomura T, Hioki K, Beuvery EC, Fitzgerald EA, Levenbook IS, Asher DM.

J Infect Dis. 1997 Feb;175(2):441-4.

PMID:
9203668
13.

Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component.

Piirainen L, Roivainen M, Litmanen L, Eskola J, Beuvery EC, Hovi T.

Vaccine. 1997 Feb;15(2):237-43.

PMID:
9066044
14.

Death rate in a small air-lift loop reactor of vero cells grown on solid microcarriers and in macroporous microcarriers.

Martens DE, Nollen EA, Hardeveld M, Velden-de Groot CA, Gooijer CD, Beuvery EC, Tramper J.

Cytotechnology. 1997 Jan;23(1-3):61-75. doi: 10.1023/B:CYTO.0000010399.23373.65.

15.

Current good manufacturing practice in plant automation of biological production processes.

Dorresteijn RC, Wieten G, van Santen PT, Philippi MC, de Gooijer CD, Tramper J, Beuvery EC.

Cytotechnology. 1997 Jan;23(1-3):19-28. doi: 10.1023/A:1007923820231.

16.

Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen.

Kersten GF, Donders D, Akkermans A, Beuvery EC.

Vaccine. 1996 Dec;14(17-18):1627-32.

PMID:
9032891
17.

On-line estimation of the biomass activity during animal-cell cultivations.

Dorresteijn RC, Numan KH, de Gooijer CD, Tramper J, Beuvery EC.

Biotechnol Bioeng. 1996 Jul 20;51(2):206-14.

PMID:
18624330
18.

Death rate in a small air-lift loop reactor of vero cells grown on solid microcarriers and in macroporous microcarriers.

Martens DE, Nollen EA, Hardeveld M, van der Velden-de Groot CA, de Gooijer CD, Beuvery EC, Tramper J.

Cytotechnology. 1996 Jan;21(1):45-59. doi: 10.1007/BF00364836.

PMID:
22358606
19.

Analysis of Bordetella pertussis suspensions by ELISA and flow cytometry.

Jiskoot W, Westdijk J, Reubsaet CH, Beuvery EC.

Adv Exp Med Biol. 1996;397:153-7. No abstract available.

PMID:
8718594
20.

A combined cell-cycle and metabolic model for the growth of hybridoma cells in steady-state continuous culture.

Martens DE, Sipkema EM, de Gooijer CD, Beuvery EC, Tramper J.

Biotechnol Bioeng. 1995 Oct 5;48(1):49-65.

PMID:
18623460
21.

Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats.

Kersten GF, Lantinga M, Hazendonk T, Beuvery EC.

Biologicals. 1995 Jun;23(2):179-83.

PMID:
7546661
22.

Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants.

Migasena S, Simasathien S, Samakoses R, Pitisuttitham P, Sangaroon P, van Steenis G, Beuvery EC, Bugg H, Bishop R, Davidson BL, et al.

Vaccine. 1995 Feb;13(2):168-74.

PMID:
7625111
23.

Batch control system vaccines: BCSV : A new man machine interface for bioreactors.

Wieten G, Dorresteijn RC, Philippi MC, Habben-Jansen M, De Clercq G, Beuvery EC.

Cytotechnology. 1995 Jan;18(1-2):57-66. doi: 10.1007/BF00744320.

PMID:
22358637
24.

Animal cell culture: Towards the 21st century.

Beuvery EC.

Cytotechnology. 1995 Jan;18(1-2):1-2. doi: 10.1007/BF00744312. No abstract available.

PMID:
22358629
25.

A method for simultaneous determination of solubility and transfer coefficient of oxygen in aqueous media using off-gas mass spectrometry.

Dorresteijn RC, de Gooijer CD, Tramper J, Beuvery EC.

Biotechnol Bioeng. 1994 Jan 20;43(2):149-54.

PMID:
18615608
26.

Effect of dilution rate on growth, productivity, cell cycle and size, and shear sensitivity of a hybridoma cell in a continuous culture.

Martens DE, de Gooijer CD, van der Velden-de Groot CA, Beuvery EC, Tramper J.

Biotechnol Bioeng. 1993 Feb 20;41(4):429-39.

PMID:
18609571
27.

Cultivation of the hybridoma cell line MN12 in a homogeneous continuous culture system: effect of culture age.

Coco-Martin JM, Martens DE, van der Velden-de Groot TA, Beuvery EC.

Cytotechnology. 1993;13(3):213-20.

PMID:
7764662
28.

Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations.

Coco-Martin JM, Brunink F, van der Velden-de Groot TA, Beuvery EC.

J Immunol Methods. 1992 Nov 5;155(2):241-8.

PMID:
1431152
29.

Instability of a hybridoma cell line in a homogeneous continuous perfusion culture system.

Coco-Martin JM, Oberink JW, Brunink F, Van der Velden-de Groot TA, Beuvery EC.

Hybridoma. 1992 Oct;11(5):653-65.

PMID:
1459588
30.

Application of electrospray mass spectrometry (ES-MS) for the analysis of monoclonal antibody Fc subunits.

Jiskoot W, van de Werken G, Martin JM, Green BN, Beuvery EC, Crommelin DJ.

Pharm Res. 1992 Jul;9(7):945-51. No abstract available.

PMID:
1438011
31.

Preparation, antigenicity, and immunogenicity of synthetic ribosylribitol phosphate oligomer-protein conjugates and their potential use for vaccination against Haemophilus influenzae type b disease.

Evenberg D, Hoogerhout P, van Boeckel CA, Rijkers GT, Beuvery EC, van Boom JH, Poolman JT.

J Infect Dis. 1992 Jun;165 Suppl 1:S152-5.

PMID:
1588151
32.
33.

The influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12).

Ressing ME, Jiskoot W, Talsma H, van Ingen CW, Beuvery EC, Crommelin DJ.

Pharm Res. 1992 Feb;9(2):266-70.

PMID:
1372732
34.

The potential of flow cytometric analysis for the characterization of hybridoma cells in suspension cultures.

Coco-Martin JM, Oberink JW, van der Velden-de Groot TA, Beuvery EC.

Cytotechnology. 1992;8(1):65-74.

PMID:
1368406
35.

Viability measurements of hybridoma cells in suspension cultures.

Coco-Martin JM, Oberink JW, van der Velden-de Groot TA, Beuvery EC.

Cytotechnology. 1992;8(1):57-64.

PMID:
1368405
36.

An isotype-specific spot-ELISA for the enumeration of antibody-secreting hybridomas and the determination of isotype switch variants.

Coco-Martin JM, Koolwijk P, van der Velden-de Groot CA, Beuvery EC.

J Immunol Methods. 1991 Dec 15;145(1-2):11-8.

PMID:
1765641
37.

Non-random conformation of a mouse IgG2a monoclonal antibody at low pH.

Jiskoot W, Bloemendal M, van Haeringen B, van Grondelle R, Beuvery EC, Herron JN, Crommelin DJ.

Eur J Biochem. 1991 Oct 1;201(1):223-32.

38.
39.

Preparation of clinical grade monoclonal antibodies from serum-containing cell culture supernatants.

Jiskoot W, Van Hertrooij JJ, Hoven AM, Klein Gebbinck JW, Van der Velden-de Groot T, Crommelin DJ, Beuvery EC.

J Immunol Methods. 1991 Apr 25;138(2):273-83.

PMID:
2033279
40.

Purification and stabilisation of a poorly soluble mouse IgG3 monoclonal antibody.

Jiskoot W, Hoven AM, De Koning AA, Leerling MF, Reubsaet CH, Crommelin DJ, Beuvery EC.

J Immunol Methods. 1991 Apr 25;138(2):181-9.

PMID:
1827821
41.

On the structure of immune-stimulating saponin-lipid complexes (iscoms).

Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJ.

Biochim Biophys Acta. 1991 Feb 25;1062(2):165-71.

PMID:
2004105
42.

Analytical approaches to the study of monoclonal antibody stability.

Jiskoot W, Beuvery EC, de Koning AA, Herron JN, Crommelin DJ.

Pharm Res. 1990 Dec;7(12):1234-41.

PMID:
2095560
43.

A purification strategy for the production of clinical grade monoclonal antibodies.

Jiskoot W, Gebbinck JW, van Hertrooij JJ, van der Velden-de Groot T, Crommelin DJ, Beuvery EC.

Dev Biol Stand. 1990;71:73-8.

PMID:
2401388
44.

New developments in the cultivation of hybridoma cells in homogeneous continuous perfusion systems.

van der Velden-de Groot TA, Martin JM, Beuvery EC.

Dev Biol Stand. 1990;71:45-54.

PMID:
2401387
45.

Characterization of antibody labelled colloidal gold particles and their applicability in a sol particle immuno assay (SPIA).

Martin JM, Pâques M, van der Velden-de Groot TA, Beuvery EC.

J Immunoassay. 1990;11(1):31-47.

PMID:
2110193
46.

Two-step purification of a murine monoclonal antibody intended for therapeutic application in man. Optimisation of purification conditions and scaling up.

Jiskoot W, Van Hertrooij JJ, Klein Gebbinck JW, Van der Velden-de Groot T, Crommelin DJ, Beuvery EC.

J Immunol Methods. 1989 Nov 13;124(1):143-56.

PMID:
2809225
47.

Subacute toxicity of Zwittergent administered intramuscularly.

Speijers GJ, Danse LH, Krajnc-Franken MA, van Leeuwen FX, Helleman PW, Beuvery EC, Vos JG, vd Heijden CA.

Vaccine. 1989 Aug;7(4):364-8.

PMID:
2815972
48.
49.

Accessibility of gonococcal and meningococcal surface antigens: immunogold labeling for quantitative electron microscopy.

Pâques M, Teppema JS, Beuvery EC, Abdillahi H, Poolman JT, Verkleij AJ.

Infect Immun. 1989 Feb;57(2):582-9.

Supplemental Content

Loading ...
Support Center